已关闭
  • 顶部Banner位
  • 固定模块
设置
BPD
试用
AI
企业管理端
厂家
Tau (Acetyl Lys174) Rabbit Polyclonal Antibody
收藏 收藏
分享
原料试剂 研发实验室
价格
¥1350.00
品牌 EnkiLife/恩玑
地区 中国,湖北省,武汉市
货号 APRab06261
产地 国产
选择规格
50μL
易享客服
EnkiLife
武汉EnkiLife-log科技有限公司
武汉
营业执照已审核
武汉恩玑生命科技有限公司(EnkiLife)是一家聚焦细胞生物学和免疫学的生物技术企业,致力于为生命科学行业的科研工作者提供高质量的产品和卓越的客户服务。 EnkiLife的产品线包括细胞系、原代细胞、培养基、血清、细胞检测试剂盒、蛋白、抗体、ELISA试剂盒、生化试剂盒等,并提供技术服务与定制开发,全方位满足生命科学行业需求,为您的实验保驾护航! EnkiLife的技术团队凭借在生物科学领域的丰富经验和专业知识,已在公司内部构建了一套完善的技术平台,涵盖细胞培养及检测、蛋白表达、抗体制备以及免疫学等多个关键领域。我们始终秉承严格的质量管理体系,优化生产流程,确保为客户提供高效、精准的技术支持。 展望未来,EnkiLife将继续致力于技术创新,不断丰富和完善我们的技术平台,以更好地满足客户需求,同时不断提升服务水平,确保客户体验的持续优化。我们期待与更多的全球科研工作者携手合作,共同推动生命科学领域的进步与发展。
进入店铺
产品规格 图文详情 技术文档
产品规格
品牌名称
EnkiLife/恩玑
货号
APRab06261
国产/进口
国产
规格
50μL
图文详情

产品概述

产品名称(Product Name)

Tau (Acetyl Lys174) Rabbit Polyclonal Antibody

描述(Description)

Rabbit Polyclonal Antibody

宿主(Host)

Rabbit

应用(Application)

WB

种属反应性(Reactivity)

Human,Rat,Mouse

 

产品性能

偶联物(Conjugation)

Unconjugated

修饰(Modification)

Acetyl Antibody

同种型(Isotype)

IgG

克隆(Clonality)

Polyclonal

形式(Form)

Liquid

存放说明(Storage)

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

储存溶液(Buffer)

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

纯化方式(Purification)

Affinity purification

 

免疫原

免疫原信息(Immunogen Information)

0

基因名(Gene Name)

MAPT MAPTL MTBT1 TAU

别名(Alternative Names)

Microtubule-associated protein tau (Neurofibrillary tangle protein) (Paired helical filament-tau) (PHF-tau)

基因ID(Gene ID)

4137

蛋白ID(SwissProt ID)

P10636

 

产品应用

稀释比(Dilution Ratio)

WB 1:500-2000; ELISA 1:5000-20000

蛋白分子量(Molecular Weight)

50-85kD

 

研究背景

This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008],alternative products:Additional isoforms seem to exist. Isoforms differ from each other by the presence or absence of up to 5 of the 15 exons. One of these optional exons contains the additional tau/MAP repeat,developmental stage:Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.,disease:Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.,disease:Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.,disease:Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia.,disease:Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson-Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.,disease:Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.,disease:In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).,domain:The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.,function:Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.,online information:Tau mutations,online information:Tau protein entry,online information:Vita minima - Issue 68 of March 2006,PTM:Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.,PTM:Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.,PTM:Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.,similarity:Contains 4 Tau/MAP repeats.,subcellular location:Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.,subunit:Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.,tissue specificity:Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.,

 

研究领域

MAPK_ERK_Growth;MAPK_G_Protein;Alzheimer's disease;

技术文档
没有您想要的资料?去索要
返回顶部